Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 4 Association of G1m status with change in DAS28 at 6 months of treatment with anti-TNF

From: Rheumatoid arthritis response to treatment across IgG1 allotype – anti-TNF incompatibility: a case-only study

      Unadjusted Adjusted b
First replication G1m genotype a number Baseline DAS28 ΔDAS28 Beta P-value Beta P-value
All patients G1m1,17+ 228 6.4 ± 1.1 2.5 ± 1.3 0.03 0.52 0.07 0.13
G1m1,17- 176 6.6 ± 1.1 2.4 ± 1.3     
INX G1m1,17+ 116 6.7 ± 0.9 2.5 ± 1.2 0.14 0.04 0.15 0.02
G1m1,17- 83 6.8 ± 1.1 2.2 ± 1.3     
ADM G1m1,17+ 112 6.1 ± 1.1 2.4 ± 1.3 −0.07 0.32 −0.01 0.83
G1m1,17- 93 6.4 ± 1.0 2.8 ± 1.3     
Second replication         
INX G1m1,17+ 203 6.2 ± 1.1 2.2 ± 1.5 0.11 0.03 0.08 0.08
G1m1,17- 159 6.1 ± 1.3 1.9 ± 1.5     
  1. aCarrier status; banalyses adjusted for baseline DAS28 and gender (and anti-TNF for All patients). ADM, adalimumab; DAS28, disease activity score in 28 joints; IFX, infliximab.
Back to article page